IN8bio, Inc. (INAB)

NASDAQ: INAB · Real-Time Price · USD

0.1216

-0.0034 (-2.72%)

May 20, 2025, 9:32 AM - Market open

IN8bio Employees

IN8bio had 18 employees as of December 31, 2024. The number of employees decreased by 13 or -41.94% compared to the previous year.

Employees

18

Change (1Y)

-13

Growth (1Y)

-41.94%

Revenue / Employee

n/a

Profits / Employee

-$1,523,611

Market Cap

11.04M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	18	-13	-41.94%
Dec 31, 2023	31	5	19.23%
Dec 31, 2022	26	7	36.84%
Dec 31, 2021	19	5	35.71%
Dec 31, 2020	14	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

INAB News

6 days ago - IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 - GlobeNewsWire
8 days ago - IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products - GlobeNewsWire
12 days ago - IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
21 days ago - IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences - GlobeNewsWire
22 days ago - IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025 - GlobeNewsWire
7 weeks ago - IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025 - GlobeNewsWire
2 months ago - IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025 - GlobeNewsWire
2 months ago - IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire